Archivos de la Sociedad Espanola de OftalmologiaOct 8, 2026

New gene-editing treatments for the front part of the eye using CRISPR-Cas9

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 9, 2026

Abstract

CRISPR-Cas9 gene editing is being applied to anterior segment disorders such as herpetic keratitis and genetically associated glaucoma.

CRISPR-Cas9 can modify specific DNA or RNA sequences to intervene in disease-related molecular pathways.
Recent advances have expanded the application of CRISPR-Cas9 beyond inherited retinal diseases to include anterior segment disorders.
Preclinical and translational findings indicate potential benefits of CRISPR-Cas9 in treating corneal and glaucomatous diseases.
Current challenges include off-target effects, immunogenicity, and difficulties with delivering the technology into ocular tissues.

Simplified

CRISPR-Cas9 gene editing has emerged as one of the most promising strategies in precision medicine applied to ophthalmology. Although its initial development focused on inherited retinal diseases, recent advances have increasingly targeted anterior segment disorders, including herpetic keratitis, hereditary corneal dystrophies, and genetically associated glaucoma. The ability to modify specific DNA or RNA sequences enables direct intervention in molecular pathways involved in inflammatory, degenerative, and infectious disease progression. This review summarizes the biological basis of CRISPR-Cas systems and discusses the main preclinical and translational findings related to corneal and glaucomatous diseases. Current limitations, including off-target effects, immunogenicity, and challenges associated with molecular delivery into ocular tissues, are also addressed. Available evidence suggests that CRISPR-Cas9 may significantly transform the future management of multiple anterior segment diseases.

Full Text

Full text is available at the source.

View Full Text ↗

New gene-editing treatments for the front part of the eye using CRISPR-Cas9

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief